Claims for Patent: 11,219,662

Summary for Patent: 11,219,662

Title:	Methods for treating hypotension in a patient that has received an ACE inhibitor by administering angiotensin II
Abstract:	The present disclosure relates to the use of angiotensin II, angiotensin III, or angiotensin IV in therapeutic methods for the treatment of hypotension, especially catecholamine-resistant hypotension.
Inventor(s):	George Tidmarsh, Lakhmir Chawla
Assignee:	La Jolla Pharma LLC
Application Number:	US17/192,453
Patent Claims:	1. A method of treating hypotension in a human patient that has received an angiotensin converting enzyme inhibitor (ACE inhibitor) within a preceding period of time of up to seven days, comprising: administering to the patient a composition comprising angiotensin II, wherein the angiotensin II is administered at an initial rate of 5 ng/kg/min or less, and titrating the rate up or down. 2. The method of claim 1, wherein the ACE inhibitor is selected from perindopril, captopril, enalapril, lisinopril, benazepril, fosinopril, moexipril, quinapril, trandolapril, and ramipril. 3. The method of claim 1, wherein the preceding period of time is one hour to seventy-two hours. 4. The method of claim 1, comprising administering angiotensin II at an initial rate of 2.5 ng/kg/min. 5. The method of claim 1, the treatment further comprising increasing the rate at which angiotensin II is administered to a final rate of less than or equal to 40 ng/kg/min. 6. The method of claim 1, the treatment further comprising decreasing the rate at which angiotensin II is administered. 7. The method of claim 1, wherein the human patient is not receiving a vasopressor. 8. The method of claim 7, wherein the human patient has an initial mean arterial pressure, and the treatment further comprises measuring the mean arterial pressure of the human patient after a subsequent period of time; and if the measured mean arterial pressure is (i) less than 75 mm Hg, or (ii) less than 10 mm Hg higher than the initial mean arterial pressure, increasing the rate at which the angiotensin II is administered to the patient. 9. The method of claim 1, wherein the human patient is receiving a vasopressor. 10. The method of claim 9, wherein the human patient has an initial mean arterial pressure, and the treatment further comprises measuring the mean arterial pressure of the human patient after a subsequent period of time; and a) if the measured mean arterial pressure is (i) at or above 75 mm Hg, or (ii) at least 10 mm Hg higher than the initial mean arterial pressure, decreasing the rate at which the vasopressor is administered to the patient; or b) if the measured mean arterial pressure is (i) less than 75 mm Hg, or (ii) less than 10 mm Hg higher than the initial mean arterial pressure, increasing the rate at which the angiotensin II is administered to the patient. 11. The method of claim 9, wherein a) if the measured mean arterial pressure is (i) at or above 85 mm Hg, or (ii) at least 10 mm Hg higher than the initial mean arterial pressure, decreasing the rate at which the vasopressor is administered to the patient; or b) if the measured mean arterial pressure is (i) less than 75 mm Hg, or (ii) less than 10 mm Hg higher than the initial mean arterial pressure, increasing the rate at which the composition comprising angiotensin II is administered to the patient. 12. The method of claim 9, wherein a) if the measured mean arterial pressure is (i) at or above 80 mm Hg, or (ii) at least 10 mm Hg higher than the initial mean arterial pressure, decreasing the rate at which the vasopressor is administered to the patient; or b) if the measured mean arterial pressure is (i) less than 70 mm Hg, or (ii) less than 10 mm Hg higher than the initial mean arterial pressure, increasing the rate at which the composition comprising angiotensin II is administered to the patient. 13. The method of claim 9, wherein a) if the measured mean arterial pressure is (i) at or above 75 mm Hg, or (ii) at least 10 mm Hg higher than the initial mean arterial pressure, decreasing the rate at which the vasopressor is administered to the patient; or b) if the measured mean arterial pressure is (i) less than 65 mm Hg, or (ii) less than 10 mm Hg higher than the initial mean arterial pressure, increasing the rate at which the angiotensin II is administered to the patient. 14. The method of claim 9, wherein the vasopressor is a catecholamine, and the catecholamine is norepinephrine, epinephrine, dopamine, or phenylephrine. 15. The method of claim 14, wherein prior to administering the composition, the patient is receiving at least 0.1 μg/kg/min of norepinephrine, at least 0.1 μg/kg/min of epinephrine, or at least 5 μg/kg/min of dopamine. 16. The method of claim 15, wherein the composition is administered until the mean arterial pressure of the patient can be maintained at or above 70 mm Hg with less than 0.1 μg/kg/min norepinephrine, less than 0.1 μg/kg/min epinephrine, or less than 15 μg/kg/min dopamine. 17. The method of claim 9, wherein the vasopressor is vasopressin, terlipressin, argipressin, desmopressin, felypressin, lypressin, or ornipressin. 18. The method of claim 17, wherein prior to administering the composition, the patient is receiving at least 0.01 U/min of vasopres sin; and/or wherein the rate at which the vasopressor is administered is decreased by at least 15%. 19. The method of claim 1, wherein the composition is administered continuously: a) for 1 to 11 days; or b) over a period of time selected from less than 6 hours; from 6 hours to 24 hours; or at least 24 hours. 20. The method of claim 1, wherein the composition is for intravenous administration. 21. The method of claim 1, wherein the patient has an initial mean arterial pressure of 70 mm Hg or less prior to administering the composition. 22. The method of claim 1, wherein the patient has an initial mean arterial pressure of 65 mm Hg or less prior to administering the composition. 23. The method of claim 1, wherein the patient has sepsis, septic shock, distributive shock, or cardiogenic shock. 24. A method of treating hypotension in a human patient that has received an angiotensin converting enzyme inhibitor (ACE inhibitor) within a preceding period of time, comprising: determining whether the patient received an angiotensin converting enzyme inhibitor (ACE inhibitor) within a preceding period of time of up to seven days; and if the patient received an ACE inhibitor within the preceding period of time administering to the patient the composition comprising angiotensin II at an initial rate of 2.5 ng/kg/min.